Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Vaccine for preventing and/or treating dengue fever

A technology for dengue fever and dengue fever virus, applied in gene therapy, peptide/protein components, biochemical equipment and methods, etc., can solve the problems of reducing the safety of dengue fever vaccine, hindering the research and development of dengue fever vaccine, etc., and achieve the effect of reducing the virulence rate

Active Publication Date: 2014-11-26
TSINGHUA UNIV
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The antibody-dependent enhancement effect greatly reduces the safety of traditional dengue fever vaccines, seriously hindering the development of dengue fever vaccines

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Vaccine for preventing and/or treating dengue fever
  • Vaccine for preventing and/or treating dengue fever
  • Vaccine for preventing and/or treating dengue fever

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] Example 1. Application of substances inhibiting mosGCTL-3 gene expression in inhibiting dengue virus replication

[0029] The C-type lectin isoform 3 of Aedes aegypti, also known as mosGCTL-3 protein, is shown in Sequence 1 of the Sequence Listing. The gene encoding the mosGCTL-3 protein is also called the mosGCTL-3 gene, and the coding region of its cDNA is shown in sequence 2 of the sequence listing.

[0030] 1. Design dsRNA

[0031] The dsRNA (dsRNA-1) designed to inhibit the expression of the mosGCTL-3 gene, that is, the double-stranded RNA corresponding to the double-stranded DNA shown in nucleotides 1 to 333 from the 5' end of Sequence 2 of the Sequence Listing.

[0032] A dsRNA (dsRNA-2) designed to inhibit GFP gene expression, the double-stranded RNA shown in SEQ ID NO: 19 of the Sequence Listing.

[0033] 2. Application of substances that inhibit the expression of mosGCTL-3 gene in inhibiting the replication of dengue fever type 2 virus

[0034] 1. Divide Ae...

Embodiment 2

[0046] Example 2. Application of substances inhibiting mosGCTL-26 gene expression in inhibiting dengue virus replication

[0047] The C-type lectin isoform 26 of Aedes aegypti is also known as mosGCTL-26 protein, as shown in sequence 3 of the sequence listing. The gene encoding the mosGCTL-26 protein is also called the mosGCTL-26 gene, and the coding region of its cDNA is shown in sequence 4 of the sequence listing.

[0048] 1. Design dsRNA

[0049] The dsRNA (dsRNA-3) designed to inhibit the expression of the mosGCTL-26 gene, that is, the double-stranded RNA corresponding to the double-stranded DNA shown in nucleotides 31-381 from the 5' end of sequence 4 of the sequence listing.

[0050] 2. Application of substances inhibiting the expression of mosGCTL-26 gene in inhibiting the replication of dengue fever type 2 virus

[0051] 1. Divide Aedes aegypti into two groups and deal with them as follows:

[0052] Experimental group: each Aedes aegypti mosquito was injected with 2...

Embodiment 3

[0063] Example 3. Application of substances inhibiting mosGCTL-15 gene expression in inhibiting dengue virus replication

[0064] The C-type lectin subtype 15 of Aedes aegypti is also called mosGCTL-15 protein, as shown in SEQ ID NO: 5 of the sequence listing. The gene encoding the mosGCTL-15 protein is also called the mosGCTL-15 gene, and the coding region of its cDNA is shown in Sequence 6 of the Sequence Listing.

[0065] 1. Design dsRNA

[0066] The dsRNA (dsRNA-4) designed to inhibit the expression of the mosGCTL-15 gene, that is, the double-stranded RNA corresponding to the double-stranded DNA shown in nucleotides 79 to 407 from the 5' end of sequence 6 of the sequence listing.

[0067] 2. Application of substances that inhibit the expression of mosGCTL-15 gene in inhibiting the replication of dengue fever type 2 virus

[0068] 1. Divide Aedes aegypti into two groups and deal with them as follows:

[0069] Experimental group: each Aedes aegypti mosquito was injected wit...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Titeraaaaaaaaaa
Login to View More

Abstract

The present invention provides a vaccine for dengue prevention and / or treatment. The present invention provides a product, and the active component thereof is a substance for inhibiting expression of the encoding gene of the C-type lectin or inhibiting activity of the C-type lectin in the aedes body. The application of the product is (a), (b), or (c) in the following: (a): inhibiting duplication of dengue virus in the aedes body; (b) dengue prevention and / or treatment; or (c) blocking spreading of dengue virus.

Description

technical field [0001] The present invention relates to a vaccine for the prevention and / or treatment of dengue fever. Background technique [0002] Dengue fever (Dengue Fever, DF) is an acute viral infectious disease transmitted by Aedes mosquitoes. Dengue virus (DENV) is spherical and consists of cell membrane, capsid protein, non-structural protein and single-stranded positive-stranded RNA. In nature, there are four serotypes of dengue virus (DENV-1, DENV-2, DENV-3 and DENV-4). After the dengue virus is transmitted to humans through the bite of Aedes mosquito, clinical symptoms can be manifested after 2-3 days of incubation. Dengue fever is clinically characterized by high fever, bone and muscle aches, bleeding tendency, and markedly reduced white blood cell counts. The clinical manifestations of dengue fever are mild, and most people recover spontaneously with the progression of the disease, and the mortality rate is low. However, the disease course of a few people wi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/12A61K48/00A61P31/14
CPCA61K38/1732A61P31/14C12N15/1138C12N2310/11
Inventor 程功刘洋
Owner TSINGHUA UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com